Mantle cell lymphoma differential diagnosis

Revision as of 21:18, 13 December 2018 by Ali Akram (talk | contribs)
Jump to navigation Jump to search

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma differential diagnosis

on Mantle cell lymphoma differential diagnosis

Mantle cell lymphoma differential diagnosis in the news

Blogs on Mantle cell lymphoma differential diagnosis

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2] Sowminya Arikapudi, M.B,B.S. [3]

Overview

Mantle cell lymphoma must be differentiated from other diseases that present similarly with B symptoms (fever, night sweats and unexplained weight loss), lymphocytosis, lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.

Differential Diagnosis

Mantle cell lymphoma must be differentiated from other diseases such as:[1][2][3]

References

  1. Elias Campo, Steven H. Swerdlow, Nancy L. Harris, Stefano Pileri, Harald Stein & Elaine S. Jaffe (2011). "The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications". Blood. 117 (19): 5019–5032. doi:10.1182/blood-2011-01-293050. PMID 21300984. Unknown parameter |month= ignored (help)
  2. Alejandra Carvajal-Cuenca, Luz F. Sua, Nhora M. Silva, Stefania Pittaluga, Cristina Royo, Joo Y. Song, Rachel L. Sargent, Blanca Espinet, Fina Climent, Samuel A. Jacobs, Jan Delabie, Kikkeri N. Naresh, Adam Bagg, Pierre Brousset, Roger A. Warnke, Sergi Serrano, Nancy Lee Harris, Steven H. Swerdlow, Elaine S. Jaffe & Elias Campo (2012). "In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior". Haematologica. 97 (2): 270–278. doi:10.3324/haematol.2011.052621. PMID 22058203. Unknown parameter |month= ignored (help)
  3. Gabor Barna, Lilla Reiniger, Peter Tatrai, Laszlo Kopper & Andras Matolcsy (2008). "The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL". Hematological oncology. 26 (3): 167–170. doi:10.1002/hon.855. PMID 18381689. Unknown parameter |month= ignored (help)

Template:Hematology

Template:WH Template:WS